{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:18:52Z","timestamp":1790151532591,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,20]],"date-time":"2012-10-20T00:00:00Z","timestamp":1350691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s11060-012-0987-0","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T12:04:16Z","timestamp":1350648256000},"page":"33-39","source":"Crossref","is-referenced-by-count":12,"title":["A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806)"],"prefix":"10.1007","volume":"111","author":[{"given":"Brian M.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K. Alfred","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadine A.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo W.","family":"Tremont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray S.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Kerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Hartford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,20]]},"reference":[{"key":"987_CR1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"987_CR2","volume-title":"WHO classification of tumours of the central nervous system","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon"},{"key":"987_CR3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845\u2013848","journal-title":"Nature"},{"key":"987_CR4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3171\/jns.1992.76.5.0792","volume":"76","author":"JA Takahashi","year":"1992","unstructured":"Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M (1992) Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76:792\u2013798","journal-title":"J Neurosurg"},{"key":"987_CR5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","volume":"236","author":"FE Kruse","year":"1998","unstructured":"Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461\u2013466","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"987_CR6","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082\u20134085","journal-title":"Proc Natl Acad Sci USA"},{"key":"987_CR7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","volume":"18","author":"HA Fine","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708\u2013715","journal-title":"J Clin Oncol"},{"key":"987_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1012554328801","volume":"54","author":"GM Marx","year":"2001","unstructured":"Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR (2001) Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54:31\u201338","journal-title":"J Neurooncol"},{"key":"987_CR9","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"987_CR10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/0895-4356(88)90025-X","volume":"41","author":"DO Dixon","year":"1988","unstructured":"Dixon DO, Simon R (1988) Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 41:1209\u20131213","journal-title":"J Clin Epidemiol"},{"key":"987_CR11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/85.9.704","volume":"85","author":"WJ Curran Jr","year":"1993","unstructured":"Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704\u2013710","journal-title":"J Natl Cancer Inst"},{"key":"987_CR12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from complete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"987_CR13","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163\u2013170","journal-title":"Cancer Chemother Rep"},{"key":"987_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables. J Roy Stat Soc 34:187\u2013220","journal-title":"J Roy Stat Soc"},{"key":"987_CR15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1078-0432.743.11.2","volume":"11","author":"R Ansiaux","year":"2005","unstructured":"Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Gregoire V, Feron O, Gallez B (2005) Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11:743\u2013750","journal-title":"Clin Cancer Res"},{"key":"987_CR16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/B:NEON.0000021803.01170.03","volume":"67","author":"F Baumann","year":"2004","unstructured":"Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, Yonekawa Y, Bernays RL (2004) Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 67:191\u2013200","journal-title":"J Neurooncol"},{"key":"987_CR17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2004.04.023","volume":"60","author":"SM Chang","year":"2004","unstructured":"Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353\u2013357","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"987_CR18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-008-9655-9","volume":"90","author":"CE Fadul","year":"2008","unstructured":"Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM (2008) A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 90:229\u2013235","journal-title":"J Neurooncol"},{"key":"987_CR19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2003.08.045","volume":"21","author":"HA Fine","year":"2003","unstructured":"Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299\u20132304","journal-title":"J Clin Oncol"},{"key":"987_CR20","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1002\/cncr.26663","volume":"118","author":"P Giglio","year":"2012","unstructured":"Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK (2012) Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118:3599\u20133606","journal-title":"Cancer"},{"key":"987_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-006-9225-y","volume":"81","author":"MD Groves","year":"2007","unstructured":"Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK (2007) A North American brain tumor consortium (NABTC 99\u201304) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81:271\u2013277","journal-title":"J Neurooncol"},{"key":"987_CR22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1215\/15228517-2008-005","volume":"10","author":"S Kesari","year":"2008","unstructured":"Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY (2008) Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 10:300\u2013308","journal-title":"Neuro Oncol"},{"key":"987_CR23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11060-010-0157-1","volume":"100","author":"CY Kim","year":"2010","unstructured":"Kim CY, Kim SK, Phi JH, Lee MM, Kim IA, Kim IH, Wang KC, Jung HL, Lee MJ, Cho BK (2010) A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol 100:193\u2013198","journal-title":"J Neurooncol"},{"key":"987_CR24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1215\/15228517-2007-060","volume":"10","author":"VK Puduvalli","year":"2008","unstructured":"Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10:216\u2013222","journal-title":"Neuro Oncol"},{"key":"987_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11060-006-9251-9","volume":"82","author":"CD Turner","year":"2007","unstructured":"Turner CD, Chi S, Marcus KJ, MacDonald T, Packer RJ, Poussaint TY, Vajapeyam S, Ullrich N, Goumnerova LC, Scott RM, Briody C, Chordas C, Zimmerman MA, Kieran MW (2007) Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol 82:95\u2013101","journal-title":"J Neurooncol"},{"key":"987_CR26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1215\/15228517-2007-006","volume":"9","author":"S Kesari","year":"2007","unstructured":"Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O\u2019Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9:354\u2013363","journal-title":"Neuro Oncol"},{"key":"987_CR27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","volume":"29","author":"A Lai","year":"2011","unstructured":"Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142\u2013148","journal-title":"J Clin Oncol"},{"key":"987_CR28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"key":"987_CR29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3322\/caac.20075","volume":"60","author":"KM Cook","year":"2010","unstructured":"Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222\u2013243","journal-title":"CA Cancer J Clin"},{"key":"987_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1006414804835","volume":"51","author":"SC Short","year":"2001","unstructured":"Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M (2001) Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 51:41\u201345","journal-title":"J Neurooncol"},{"key":"987_CR31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00004424-199906000-00007","volume":"34","author":"O Tynninen","year":"1999","unstructured":"Tynninen O, Aronen HJ, Ruhala M, Paetau A, Von Boguslawski K, Salonen O, Jaaskelainen J, Paavonen T (1999) MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34:427\u2013434","journal-title":"Invest Radiol"},{"key":"987_CR32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11912-010-0143-y","volume":"13","author":"EC Quant","year":"2011","unstructured":"Quant EC, Wen PY (2011) Response assessment in neuro-oncology. Curr Oncol Rep 13:50\u201356","journal-title":"Curr Oncol Rep"},{"key":"987_CR33","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972","journal-title":"J Clin Oncol"},{"key":"987_CR34","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1038\/sj.onc.1204258","volume":"20","author":"JS Park","year":"2001","unstructured":"Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P (2001) Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 20:3266\u20133280","journal-title":"Oncogene"},{"key":"987_CR35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1158\/1078-0432.CCR-09-3287","volume":"16","author":"L Seymour","year":"2010","unstructured":"Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D (2010) The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16:1764\u20131769","journal-title":"Clin Cancer Res"},{"key":"987_CR36","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1200\/JCO.2011.39.8420","volume":"30","author":"L Trippa","year":"2012","unstructured":"Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM (2012) Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 30:3258\u20133263","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-012-0987-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0987-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T12:25:30Z","timestamp":1714479930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-012-0987-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,20]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s11060-012-0987-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,20]]}}}